South Dakota Investment Council Xencor Inc Transaction History

South Dakota Investment Council

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$19.74 - $29.01 $85,059 - $125,004	-4,309 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$26.68 - $41.63 $1.88 Million - $2.94 Million	-70,570 Reduced 94.25%	4,309 $115,000
Q3 2021 Nov 09, 2021	SELL	$30.65 - $35.68 $1.52 Million - $1.77 Million	-49,569 Reduced 39.83%	74,879 $2.45 Million
Q2 2021 Aug 11, 2021	BUY	$34.33 - $44.68 $207,662 - $270,269	6,049 Added 5.11%	124,448 $4.29 Million
Q1 2021 May 13, 2021	BUY	$40.81 - $53.88 $15,058 - $19,881	369 Added 0.31%	118,399 $5.1 Million
Q3 2020 Nov 06, 2020	BUY	$30.09 - $43.02 $797,385 - $1.14 Million	26,500 Added 28.95%	118,030 $4.58 Million
Q2 2020 Aug 13, 2020	BUY	$27.76 - $33.42 $2.06 Million - $2.48 Million	74,130 Added 426.03%	91,530 $2.97 Million
Q1 2020 May 11, 2020	BUY	$20.69 - $37.79 $80,691 - $147,381	3,900 Added 28.89%	17,400 $520,000
Q4 2019 Feb 11, 2020	BUY	$32.75 - $41.43 $203,050 - $256,866	6,200 Added 84.93%	13,500 $464,000
Q3 2019 Nov 13, 2019	BUY	$33.73 - $46.27 $246,228 - $337,771	7,300 New	7,300 $246,000

216

71.8M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.42B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of South Dakota Investment Council, based on Form 13F filings with the SEC.

Stay updated on South Dakota Investment Council with notifications on news.